Ribas, A. & Wolchok, J. D. Most cancers immunotherapy utilizing checkpoint blockade. Science 359, 1350–1355 (2018).
Rohaan, M. W. et al. Tumor-infiltrating lymphocyte remedy or ipilimumab in superior melanoma. N. Engl. J. Med. 387, 2113–2125 (2022).
Rosenberg, S. A. & Restifo, N. P. Adoptive cell switch as personalised immunotherapy for human most cancers. Science 348, 62–68 (2015).
Klebanoff, C. A., Chandran, S. S., Baker, B. M., Quezada, S. A. & Ribas, A. T cell receptor therapeutics: immunological focusing on of the intracellular most cancers proteome. Nat. Rev. Drug Discov. 22, 996–1017 (2023).
Simoni, Y. et al. Bystander CD8+ T cells are plentiful and phenotypically distinct in human tumour infiltrates. Nature 557, 575–579 (2018).
Scheper, W. et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat. Med. 25, 89–94 (2019).
Schumacher, T. N., Scheper, W. & Kvistborg, P. Most cancers neoantigens. Annu. Rev. Immunol. 37, 173–200 (2019).
Schumacher, T. N. & Schreiber, R. D. Neoantigens in most cancers immunotherapy. Science 348, 69–74 (2015).
Gros, A. et al. Potential identification of neoantigen-specific lymphocytes within the peripheral blood of melanoma sufferers. Nat. Med. 22, 433–438 (2016).
Gubin, M. M. et al. Checkpoint blockade most cancers immunotherapy targets tumour-specific mutant antigens. Nature 515, 577–581 (2014).
Rizvi, N. A. et al. Most cancers immunology. Mutational panorama determines sensitivity to PD-1 blockade in non-small cell lung most cancers. Science 348, 124–128 (2015).
Alspach, E. et al. MHC-II neoantigens form tumour immunity and response to immunotherapy. Nature 574, 696–701 (2019).
Oh, D. Y. et al. Intratumoral CD4+ T cells mediate anti-tumor cytotoxicity in human bladder most cancers. Cell 181, 1612–1625 (2020).
Tran, E. et al. Most cancers immunotherapy based mostly on mutation-specific CD4+ T cells in a affected person with epithelial most cancers. Science 344, 641–645 (2014).
Borst, J., Ahrends, T., Babala, N., Melief, C. J. M. & Kastenmuller, W. CD4+ T cell assist in most cancers immunology and immunotherapy. Nat. Rev. Immunol. 18, 635–647 (2018).
Hu, Z. et al. A cloning and expression system to probe T-cell receptor specificity and assess useful avidity to neoantigens. Blood 132, 1911–1921 (2018).
Guo, X. Z. et al. Speedy cloning, expression, and useful characterization of paired αβ and γδ T-cell receptor chains from single-cell evaluation. Mol. Ther. Strategies Clin. Dev. 3, 15054 (2016).
Zong, S. et al. Very speedy cloning, expression and figuring out specificity of T-cell receptors for T-cell engineering. PLoS ONE 15, e0228112 (2020).
Genolet, R. et al. TCR sequencing and cloning strategies for repertoire evaluation and isolation of tumor-reactive TCRs. Cell Rep. Strategies 3, 100459 (2023).
Fahad, A. S. et al. Immortalization and useful screening of natively paired human T cell receptor repertoires. Protein Eng. Des. Sel. 35, gzab034 (2022).
Spindler, M. J. et al. Massively parallel interrogation and mining of natively paired human TCRαβ repertoires. Nat. Biotechnol. 38, 609–619 (2020).
Muller, T. R. et al. A T-cell reporter platform for high-throughput and dependable investigation of TCR operate and biology. Clin. Transl. Immunol. 9, e1216 (2020).
Fahad, A. S. et al. Cell activation-based screening of natively paired human T cell receptor repertoires. Sci. Rep. 13, 8011 (2023).
Vazquez-Lombardi, R. et al. Excessive-throughput T cell receptor engineering by useful screening identifies candidates with enhanced efficiency and specificity. Immunity 55, 1953–1966 (2022).
Cattaneo, C. M. et al. Identification of patient-specific CD4+ and CD8+ T cell neoantigens by HLA-unbiased genetic screens. Nat. Biotechnol. 41, 783–787 (2023).
Lowery, F. J. et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 375, 877–884 (2022).
Gros, A. et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J. Clin. Make investments. 124, 2246–2259 (2014).
Arnaud, M. et al. Delicate identification of neoantigens and cognate TCRs in human strong tumors. Nat. Biotechnol. 40, 656–660 (2022).
Foy, S. P. et al. Non-viral precision T cell receptor alternative for personalised cell remedy. Nature 615, 687–696 (2022).
Hilf, N. et al. Actively personalised vaccination trial for newly identified glioblastoma. Nature 565, 240–245 (2019).
Ott, P. A. et al. An immunogenic private neoantigen vaccine for sufferers with melanoma. Nature 547, 217–221 (2017).
Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic information throughout totally different situations, applied sciences, and species. Nat. Biotechnol. 36, 411–420 (2018).
Lefranc, M. P. et al. IMGT®, the worldwide ImMunoGeneTics data system® 25 years on. Nucleic Acids Res. 43, D413–D422 (2015).
Chen, X. & Porter, E. Compositions and strategies for T-cell receptor gene meeting. Patent WO2020206238A2 (2020).
Klein, J. C. et al. Multiplex pairwise meeting of array-derived DNA oligonucleotides. Nucleic Acids Res. 44, e43 (2016).
Chapuis, A. G. et al. T cell receptor gene remedy focusing on WT1 prevents acute myeloid leukemia relapse post-transplant. Nat. Med. 25, 1064–1072 (2019).
Schmitt, T. M., Greenberg, P. D. & Nguyen, H. N. T cell immunotherapy particular for WT-1. US patent US20160083449A1 (2015).
Borbulevych, O. Y., Santhanagopolan, S. M., Hossain, M. & Baker, B. M. TCRs utilized in most cancers gene remedy cross-react with MART-1/Melan-A tumor antigens through distinct mechanisms. J. Immunol. 187, 2453–2463 (2011).
Johnson, L. A. et al. Gene switch of tumor-reactive TCR confers each excessive avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J. Immunol. 177, 6548–6559 (2006).
Kwakkenbos, M. J. et al. Era of steady monoclonal antibody–producing B cell receptor–constructive human reminiscence B cells by genetic programming. Nat. Med. 16, 123–128 (2010).
Moravec, Z. et al. Useful discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening: validation in CD8 T cells. NCBI Sequence Learn Archive https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1068078 (2024).
Moravec, Z. et al. Useful discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening: validation in CD4 T cells and OVC190 TCR display screen. NCBI Sequence Learn Archive https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1068299 (2024).
Moravec, Z. et al. Useful discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening: NKIRTIL063 titration display screen. NCBI Sequence Learn Archive https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1068301 (2024).
Moravec, Z. et al. Useful discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening: NKIRTIL063 neoantigen display screen. NCBI Sequence Learn Archive https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1068303 (2024).